<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04369443</url>
  </required_header>
  <id_info>
    <org_study_id>2020-110</org_study_id>
    <nct_id>NCT04369443</nct_id>
  </id_info>
  <brief_title>Application of Large Volume Acute Normovolemic Hemodilution in Cardiac Surgery</brief_title>
  <official_title>Application of Large Volume Acute Normovolemic Hemodilution in Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The application of acute Normovolemic Hemodilution in cardiac surgery can effectively reduce
      perioperative blood transfusion, reduce postoperative complications and mortality, and is a
      low-cost, operable and effective blood protection measure.For the application of Acute
      Normovolemic Hemodilution in heart surgery, we still face an urgent problem: to what extent
      can Acute Normovolemic Hemodilution achieve better &quot;blood saving effect&quot;, that is, whether a
      large number of Acute Normovolemic Hemodilution can reduce perioperative blood transfusion to
      a greater extent
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 24, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Volume of allogeneic blood transfusion</measure>
    <time_frame>Through study completion，about 8 months</time_frame>
    <description>The mean volume of allogeneic blood transfusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of postoperative cardiac complications</measure>
    <time_frame>Through study completion，about 8 months</time_frame>
    <description>Including myocardial infarction, heart failure, low cardiac output, pericardial tamponade, severe arrhythmia according to physical and laboratory examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of postoperative pulmonary complications</measure>
    <time_frame>Through study completion，about 8 months</time_frame>
    <description>Including moderate and massive pleural effusion, respiratory failure, re-intubation according to physical and laboratory examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of postoperative renal complication</measure>
    <time_frame>Through study completion，about 8 months</time_frame>
    <description>Acute kidney injury or Need renal replacement therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other severe complication</measure>
    <time_frame>Through study completion，about 8 months</time_frame>
    <description>Including re-operation, re-admission of intensive care unit, multiple organ dysfunction, all cause death according to physical and laboratory examination and medical record</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Cardiac Surgery</condition>
  <condition>Acute Normovolemic Hemodilution</condition>
  <arm_group>
    <arm_group_label>MANH</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LANH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Large volume Acute Normovolemic Hemodilution</intervention_name>
    <description>Following induction of anesthesia, the volume of blood to be removed during Acute Normovolemic Hemodilution was calculated using an established formula:V=Weight（Kg）×12-15（mL/Kg）;Blood to be removed was capped at： Vmax=EVB×(Hi-Hf)/Hav（EBV= estimated blood volume （male:70mL/Kg，female:65mL/Kg）；Hi= initial hemoglobin ；Hf=target Hb（ 10g/dL ）；Hav= the average of the initial and minimal allowable hemoglobin）.Ensure the volume of removed blood does not exceed the upper limit and Hb ≥10g/dL after blood removed.</description>
    <arm_group_label>LANH</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  （1）18-75years old;（2）elective cardiac surgery under cardiopulmonary bypass;
             （3）Preoperative hemoglobin (Hb) ≥ 12g/dl; (4) Transfusion Risk Understanding Scoring
             Tool (TRUST) ≥ 2 (possibility of blood transfusion ≥40%).

        Exclusion Criteria:

          -  （1）congenital heart disease、Cardiac tumor、aortic dissection、heart
             transplantation（2）Low body weight（&lt;50 kg）;（3）preoperative shock；（4）myocardial
             infarction within 3 months before surgery；（5）ischemic heart disease;Left main coronary
             artery stenosis &gt;70%;Severe aortic stenosis (area &lt; 0.7cm2);Severe changes in left
             ventricular function (ejection fraction &lt;30%, requiring vasoactive agents to assist
             circulation);（6）severe carotid artery stenosis (&gt;70% or with symptoms);（7） kidney
             failure (blood creatinine level &gt;442 mmol/L) or dialysis treatment;（8） serum albumin
             level (ALB) is less than 25 g/L.（9） international standardized ratio (INR) &gt;1.5 or
             platelet count &lt;100 103/mm3;（10）Inherited/acquired coagulation function
             defect;（11）contagious or infectious diseases;（12） patient or family members refused to
             participate in research;（13）refused to infusion of autologous blood or allogeneic
             blood products
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min Yan, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>The second affiliated hospital of Zhejiang University hangzhou, Zhejiang, China, 310000</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yue Ming, Master</last_name>
    <phone>15858287132</phone>
    <email>1120596162@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Min Yan, Doctor</last_name>
    <email>zryanmin@zju.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Zhejiang University anesthesiology department</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Yan, Doctor</last_name>
      <email>zryanmin@zju.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 28, 2020</study_first_submitted>
  <study_first_submitted_qc>April 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2020</study_first_posted>
  <last_update_submitted>April 28, 2020</last_update_submitted>
  <last_update_submitted_qc>April 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

